

Exploration of Targeted Anti-tumor Therapy

Highly Cited Paper Award Winners (2020-2024)

2020-2021

Current strategies for the design of PROTAC linkers: a critical review

Robert I. Troup, Charlene Fallan *, Matthias G. J. Baud *

Published: October 30, 2020 DOI: https://doi.org/10.37349/etat.2020.00018

Special Issue: Proteolysis Targeting Chimera (PROTAC)

The impact of tumour pH on cancer progression: strategies for clinical intervention

Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon *

Published: April 28, 2020 DOI: https://doi.org/10.37349/etat.2020.00005

Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients

Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana Arance, Adriana García, Llucia Alos †, Cristina Teixido †*

Published: April 28, 2020 DOI: https://doi.org/10.37349/etat.2020.00006

Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer

Sosmitha Girisa, Dey Parama, Choudhary Harsha, Kishore Banik, Ajaikumar B. Kunnumakkara *

Published: October 30, 2020 DOI: https://doi.org/10.37349/etat.2020.00019

Special Issue: Targeting Transcription Factors for Cancer Therapy

Role of liquid biopsy for thoracic cancers immunotherapy

Raimondo Di Liello*, Flora Cimmino, Soraya Simón, Emilio Francesco Giunta, Vincenzo De Falco, Paloma Martín-Martorell

Published: June 29, 2020 DOI: https://doi.org/10.37349/etat.2020.00012

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors

Rachael Arthur, Beatriz Valle-Argos, Andrew J. Steele, Graham Packham *

Published: June 29, 2020 DOI: https://doi.org/10.37349/etat.2020.00009

Special Issue: Proteolysis Targeting Chimera (PROTAC)

2022

Current strategies for the design of PROTAC linkers: a critical review

Robert I. Troup, Charlene Fallan *, Matthias G. J. Baud *

Published: October 30, 2020 DOI: https://doi.org/10.37349/etat.2020.00018

Special Issue: Proteolysis Targeting Chimera (PROTAC)

The impact of tumour pH on cancer progression: strategies for clinical intervention

Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon *

Published: April 28, 2020 DOI: https://doi.org/10.37349/etat.2020.00005



The clinical advances of proteolysis targeting chimeras in oncology

Hao Xie *, Junjia Liu, Diego M. Alem Glison, Jason B. Fleming

Published: December 31, 2021 DOI: https://doi.org/10.37349/etat.2021.00061

Special Issue: Proteolysis Targeting Chimera (PROTAC)

2023

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Kira-Lee Koster, Jens Huober, Markus Joerger *

Published: June 23, 2022 DOI: https://doi.org/10.37349/emed.2022.00089

Special Issue: Disease Diagnosis, Molecular Mechanism and Therapeutic Strategies in Kidney Injury and Fibrosis

Potential role of resveratrol and its nano-formulation as anti-cancer agent

Akshay Kumar, Balak Das Kurmi, Amrinder Singh, Dilpreet Singh *

Published: October 31, 2022 DOI: https://doi.org/10.37349/etat.2022.00105

Special Issue: Plant Extracts as an Infinite Resource for New Anticancer Agents

2024

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Vincenza Caputo, Fortunato Ciardiello, Carminia Maria Della Corte, Giulia Martini, Teresa Troiani, Stefania Napolitano *

Published: February 28, 2023 DOI: https://doi.org/10.37349/etat.2023.00125

Special Issue: The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor

Liquid biopsy and glioblastoma

Robert H. Eibl *, Markus Schneemann

Published: February 25, 2023 DOI: https://doi.org/10.37349/etat.2023.00121

Special Issue: Theranostic Frontiers in Neuro-Oncology